American Society of Transplantation and Cellular Therapy Series: #8- Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients.

IF 3.6 3区医学 Q2 HEMATOLOGY Transplantation and Cellular Therapy Pub Date : 2025-02-07 DOI:10.1016/j.jtct.2025.01.892

A P Douglas, F Lamoth, T M John, A H Groll, T L Shigle, G A Papanicolaou, R F Chemaly, P A Carpenter, S S Dadwal, T J Walsh, D P Kontoyiannis

{"title":"American Society of Transplantation and Cellular Therapy Series: #8- Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients.","authors":"A P Douglas, F Lamoth, T M John, A H Groll, T L Shigle, G A Papanicolaou, R F Chemaly, P A Carpenter, S S Dadwal, T J Walsh, D P Kontoyiannis","doi":"10.1016/j.jtct.2025.01.892","DOIUrl":null,"url":null,"abstract":"<p><p>The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to create a guideline focusing on non-Aspergillus invasive molds, which are uncommon yet lethal invasive fungal diseases in the peri-HCT period. We used a compendium-style approach by dissecting this broad, heterogeneous and highly complex topic into a series of standalone frequently asked questions (FAQs) and tables. Adult and pediatric infectious diseases and HCT content experts developed, then answered FAQs, and finalized topics with harmonized recommendations. All the evidence for NAIMI is non-RCT and mostly level III, therefore there are no recommendation grades and instead key references are provided. Through this format, this \"8th\" topic in the series focuses on the relevant risk factors, diagnostic considerations, prophylaxis and treatment approaches relevant to rare mold infections in the pre- and post-transplant periods.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2025.01.892","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to create a guideline focusing on non-Aspergillus invasive molds, which are uncommon yet lethal invasive fungal diseases in the peri-HCT period. We used a compendium-style approach by dissecting this broad, heterogeneous and highly complex topic into a series of standalone frequently asked questions (FAQs) and tables. Adult and pediatric infectious diseases and HCT content experts developed, then answered FAQs, and finalized topics with harmonized recommendations. All the evidence for NAIMI is non-RCT and mostly level III, therefore there are no recommendation grades and instead key references are provided. Through this format, this "8th" topic in the series focuses on the relevant risk factors, diagnostic considerations, prophylaxis and treatment approaches relevant to rare mold infections in the pre- and post-transplant periods.

查看原文